Tetraphase Pharmaceuticals

Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.

BioCryst Pharmaceuticals

ElectroCore Inc

PDS Biotechnology Corporation

Cardiff Oncology

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you today.

Top Stocks To Short As Dow Surges From Boeing Gains

FuelCell Energy

Intellicheck

MannKind

We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology have identified several Top Shorts for you to hedge the market with.

Top Stocks To Short Following Fed's New Restrictions For Big Banks

SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that they have entered into a definitive merger agreem

La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.

La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company (“La Jolla”) to acquire Tetraphase for $43.0 million in cash, plus an additional aggregate amount of $16.0 million in

Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta

Blink Charging

Cocrystal Pharma

With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio with or bet against overall.

Top Stocks To Short As Markets Continue To Fluctuate

DermTech Inc

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified several top shorts for your portfolio.

Top Companies To Short As Stock Market Continues To Rally

Tetraphase (TTPH) delivered earnings and revenue surprises of 19.63% and -28.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Lags Revenue Estimates

Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.

Bidding War Sends Tetraphase Shares Soaring

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know

During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?

Tetraphase Pharmaceuticals (TTPH) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q3 2019 Results - Earnings Call Transcript

Tetraphase (TTPH) delivered earnings and revenue surprises of 4.31% and 115.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Tops Revenue Estimates

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q2 2019 Results - Earnings Call Transcript

Tetraphase (TTPH) delivered earnings and revenue surprises of -10.53% and -49.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Lags Revenue Estimates

Earnings Preview: Tetraphase Pharmaceuticals (TTPH) Q2 Earnings Expected to Decline

Tetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q1 2019 Results - Earnings Call Transcript

Tetraphase (TTPH) delivered earnings and revenue surprises of 7.69% and -34.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Guy Macdonald on Q4 2018 Results - Earnings Call Transcript

News for Tetraphase Pharmaceuticals Stock (TTPH)